D.M is chronic, metabolic disease characterized by elevated levels of blood glucose. There are many types of antidiabetic drugs such as insulin, biguanides, sulfonylurea, glinide, Thiazodinediones, Glucose Sodium cotransporter2 inhibitors, a- glycoside inhibitors and DPP4 inhibitors.

Dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin, vildagliptin, tiniglipten) are a successful class of antidiabetic agents which improve glycaemic control with similar efficacy to other oral agents that acts on incretin hormones, mainly GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory peptide) and associated with a low incidence of adverse events.

A comparative study of 58 patients were included in this study, including 48 diabetic patients and 10 non-diabetic patients. The diabetic patients were divided into three groups based on the type of DPP4 inhibitor they were taking.